Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Nashville, Tennessee

Cancer biologic therapy trials in Nashville, TN

59 cancer biologic therapy studies are recruiting participants at sites in Nashville as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 59 studies are recruiting at a site in Nashville.
  • By phase: Phase 1 (11), Phase 1/2 (10), Phase 2 (17), Phase 2/3 (2), Phase 3 (17), Observational (2).
  • By sponsor: industry (41), university, hospital or other (10), government (8).
  • By research area: Lymphoma (20), Lung Cancer (15), Breast Cancer (14), Melanoma (5), Prostate Cancer (5).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Nashville

Basic details from each study's public record (the 30 most recently updated of 59). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT05422794 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05564377 · updated
  3. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    One Oncology - Tennessee Oncology ( Site 0098) · SCRI Oncology Partners ( Site 7000) · Tennessee Oncology ( Site 0111)
    Registry record
    NCT06393374 · updated
  4. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
    Registry record
    NCT06841354 · updated
  5. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
    Registry record
    NCT06966700 · updated
  6. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT06797635 · updated
  7. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07652242 · updated
  8. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    SCRI Oncology Partners ( Site 7000) · Tennessee Oncology ( Site 0068)
    Registry record
    NCT07060807 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Lung cancer studies recruiting in Nashville

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Study site
    Clinical Study Sites
    Registry record
    NCT06767514 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Elliston Place Medical Oncology & Hematology ( Site 0215)
    Registry record
    NCT06623422 · updated
  3. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
    Registry record
    NCT07221474 · updated
  4. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06646276 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Prostate cancer studies recruiting in Nashville

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT03866382 · updated
  2. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Juri Biosciences, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07824349 · updated
  3. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Tennessee Oncology Nashville
    Registry record
    NCT07164443 · updated
  4. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    Sarah Cannon Research
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Melanoma studies recruiting in Nashville

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nashville, TN on ClinicalTrials.gov.

Lymphoma studies recruiting in Nashville

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT06317662 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT06717347 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7002)
    Registry record
    NCT06890884 · updated
  4. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
    Registry record
    NCT07519772 · updated
  5. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SCRI Oncology Partners ( Site 7000)
    Registry record
    NCT07634471 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05675410 · updated
  8. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT07003295 · updated
  9. A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Umoja Biopharma
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT07735533 · updated
  10. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    Sarah Cannon Research Institute Oncology Partners
    Registry record
    NCT07015242 · updated
  11. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07188558 · updated
  12. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06500273 · updated
  13. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT06124157 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call